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Abstract
Goals of work Critical weight loss (≥5% in 1 month or
≥10% in 6 months) is a common phenomenon in head and
neck cancer patients. It is unknown which complaints are
most strongly related to critical weight loss in head and
neck cancer patients at the time of diagnosis. The aim of
this explorative study was to assess the prevalence of
critical weight loss and to analyze risk factors for critical
weight loss in head and neck cancer patients before
treatment.
Materials and methods Critical weight loss and factors
reducing dietary intake were assessed in 447 patients referred
to an ear, nose and throat clinic at the time of diagnosis.
Main results In total, data of 407 patients were analyzed.
Critical weight loss was present in 19% of the patients.
Patients with cancer in the hypopharynx, oropharynx/oral
cavity and supraglottic larynx had the highest risk for
critical weight loss. Loss of appetite, dysphagia/passage
difficulties and loss of taste/aversion were significantly
(p<0.05) associated with critical weight loss.
Conclusions Already before treatment, critical weight loss
is a considerable problem in head and neck cancer patients.
Critical weight loss is frequently observed in patients with
cancer in the hypopharynx, oropharynx/oral cavity and
supraglottic larynx.
Keywords Weight loss . Malnutrition .
Head and neck cancer . Prevalence . Risk factors
Introduction
Critical weight loss (CWL), defined as the involuntary
weight loss of ≥5% in 1 month or ≥10% in 6 months, is a
common phenomenon in head and neck cancer patients
because it is present in about 30% to 55% of these patients
[5, 17, 19, 28]. CWL is clinically of utmost importance. It
is associated with increased morbidity and mortality. CWL
may result in an increased complication rate, such as
impaired wound healing, reduced immune function and
decreased tolerance to surgery, radiotherapy and chemo-
therapy [2, 25, 28]. CWL also reduces disease-related
quality of life and functional status [27].
Head and neck cancer patients often experience com-
plaints related to the localization of the tumor, such as
dysphagia, odynophagia, passage difficulties and pain in
the mouth [6, 7, 9, 10, 18]. Furthermore, systemic effects of
the tumor may result in changes in taste or appetite [15, 22].
These complaints may result in difficulties with nutritional
intake leading to CWL. It is unknown, however, which
complaints are most strongly related to CWL in head and
neck cancer patients at the time of diagnosis.
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The aim of this explorative study was to assess the
prevalence of CWL and to analyze the risk factors for CWL
before treatment in head and neck cancer patients referred
to the ear, nose and throat (ENT) department of the
University Medical Center Groningen (UMCG).
Materials and methods
Patients with a newly diagnosed tumor in the head and neck
region, either a (second) primary or a recurrent tumor, were
screened according to the UMCG Head and Neck Clinical
Screening Tool (UMCG H&N CST) as a part of a routine
clinical procedure at the ENT department of the UMCG.
The screening was performed by an ENT physician or a
nurse, at the first visit at the ENT department or at the time
of endoscopic diagnostic investigation, usually about
2 weeks after the first visit.
The UMCG H&N CST consisted of two parts. The first
part assessed CWL, defined as weight loss of ≥5% in
1 month or ≥10% in 6 months [1, 2, 4, 8, 25, 28].
Assessment of CWL was based upon the formula [normal
weight (kg)−actual weight (kg)]/normal weight (kg)×
100%]. CWL was recorded as a dichotomous variable
(present/absent). The second part of the UMCG H&N CST
assessed symptoms that may lead to difficulties with
nutritional intake, including loss of appetite, dysphagia,
passage difficulties, pain in the throat, loss of taste/
aversion, dry mouth and pain in the mouth. These
symptoms were recorded also dichotomously (present/
absent). In addition, tumor localization and tumor size of
each patient were obtained from the medical records after
diagnostics.
The data of 447 consecutive patients with a tumor in the
head and neck region, screened between November 2001
and August 2004, were used for this study. For data
analysis, SPSS version 12.0 (SPSS, Chicago) was used.
Descriptive statistics were used to assess the prevalence of
CWL. Stepwise multivariate logistic regression was used to
identify risk factors for CWL. The presence or absence of
CWL was used as the dependent variable, and the
symptoms possibly influencing nutritional status were used
as the independent variables. The influence of the tumor
size (T) on CWL was calculated by means of chi-square
analysis. A p value <0.05 was considered statistically
significant.
Results
Data of 407 patients out of 447 (91%) of the UMCG H&N
CST were complete. Patient characteristics of patients with
complete (91%) and incomplete (9%) data sets are
summarised in Table 1. Significantly more patients with a
tumor of hypopharynx, oropharynx/oral cavity or supra-
glottic larynx had an incomplete data set compared to
patients with other tumor localizations (p=0.038) and
significantly more patients with a T3 or T4 tumor had an
incomplete data set compared to patients with a T1 or T2
tumor (p=0.003). CWL was present in 19% (77/407) of the
patients. Prevalence of CWL did not differ significantly
between patients with a newly diagnosed primary tumor
(19%, 71/371 CWL) and patients with a recurrent tumor
(17%, 6/36 CWL).













Percentage Number Percentage Number
Gender
Male 74 302 80 32
Female 26 105 20 8
Tumor typea
Primary tumor 91 371 83 33
Recurrent tumor 9 36 18 7
Tumor localizationa,b
Larynx 31 125 28 11
Supraglottic
larynx
9 38 13 5
Glottic larynx 26 107 8 3
Sub-/transglottic
larynx
2 9 8 3
Oropharynx 15 62 23 9
Hypopharynx 12 49 20 8
Nasopharynx 3 14 10 4
Oral cavity 2 6 3 1
Otherc 30 122 18 7
Tumor sizea,d
T1 20 82 13 5
T2 19 77 5 2
T3 8 32 18 7
T4 18 75 30 12
Not recordede 35 141 35 14
a Total percentage is not similar to 100 due to rounding off.
Percentages are column percentages.
b Significantly more patients with a tumor of the hypopharynx,
oropharynx/oral cavity or supraglottic larynx had an incomplete data
set compared to patients with other tumor localizations (p=0.038).
c Carcinoma in the ear, salivary gland, nose/paranasal cavity, esoph-
agus, thyroid gland, skin, eye, lymphoma and unknown primary.
d Significantly more patients patients with a T3 or a T4 tumor had an
incomplete data set compared to patients with a T1 or a T2 tumor
(p=0.003).
e From the tumors listed as ‘other’, no classifications of tumor size
were made.
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Critical weight loss related to tumor localization
CWL related to tumor localization is presented in Table 2.
Tumor localizations in which CWL was present in more
than 30% of the patients were the oropharynx/oral cavity,
nasopharynx and hypopharynx. Although the prevalence
of CWL in patients with laryngeal cancer was low (12%,
18/154), within this group of patients, patients with
supraglottic laryngeal cancer had CWL more frequently
(34%, 13/38).
In total, 122 patients had a tumor at 1 of the
following sites: ear, salivary gland, nose/paranasal cavity,
esophagus, thyroid gland, skin, eye or lymphoma or had
an unknown primary tumor. If this group of patients with
tumor localizations registered as ‘other’ was excluded
from the analysis, the prevalence of CWL increased to
24% (67/285).
Predictive symptoms for critical weight loss
Dysphagia and/or passage difficulties were most frequently
reported in patients with hypopharyngeal cancer and the
group of patients with cancer in the oropharynx/oral cavity
(Table 3). Dysphagia and/or passage difficulties, loss of
taste/aversion and loss of appetite were significantly
associated (p<0.05, logistic multivariate regression analy-
sis) with CWL (82% correctly predicted) (Table 4).
Loss of taste/aversion was significantly (p<0.05) present
more frequently in patients with tumor sizes 3 and 4 (11%,
11/102) than in patients with tumor sizes 1 and 2 (3%,
4/143). Patients with tumor sizes 3 and 4 also reported
significantly (p<0.001) more frequent loss of appetite
(28%, 28/102) than patients with tumor sizes 1 and 2
(5%, 7/143).
Finally, CWL was significantly (p<0.001) present more
frequently in patients with tumor sizes 3 and 4 (43%, 46/107)
than in patients with tumor sizes 1 and 2 (7%, 12/159).
Discussion
In the current study, CWL was present in one fifth of all
patients. Other studies in which CWL was assessed in head
and neck cancer patients before treatment reported preva-
lences varying from 31% to 57% [17, 19, 28]. Our lower
prevalence may be explained by the timing of the
assessment. In our study, CWL was assessed at the time
of diagnosis, while patients in the other studies were
assessed on starting radiotherapy or on the day before
surgery. Initial surgery or radiotherapy is usually 2 to
6 weeks after diagnosis, while post-operative radiotherapy
is usually 4 to 6 weeks after surgery. The extent of the
weight loss may increase in the period between diagnosis
and start of the treatment, specifically if dysphagia or
passage difficulties are present.
Distribution of tumor localization in the current study
differed from those reported in previous studies. In two of
the three studies in which CWL was studied before
treatment, significantly more patients with cancer in the
oral cavity were included (respectively 10% and 43%
instead of 1% in our study) [17, 19]. In the other study,
distribution of tumor localizations was not given [28]. In
the UMCG, patients with cancer in the oral cavity are
predominantly treated at the oral and maxillofacial surgery
department and only a few of these patients are treated at
the ENT department. This phenomenon may have resulted
in an underestimation of the prevalence of CWL in head
and neck cancer patients because patients with cancer in the
oral cavity are at risk for CWL due to dysphagia and
chewing problems. No information was given about the
prevalence of CWL within the various tumor localizations
in previous studies [17, 19, 28]. This information is relevant
as we showed that prevalence of CWL varies greatly
between various tumor localizations. Therefore, it is not
known if differences in distribution of tumor localizations
can explain the differences between total prevalences of
CWL reported in the other studies.
In the current study, data were incomplete of only 9% of
the patients. More data were incomplete in patients with a
tumor in the hypopharynx, oropharynx/oral cavity and
supraglottic larynx and in patients with T3/T4 tumors than
in patients with tumors at the other localizations studied or
with T1/T2 tumors. These tumor localizations and tumor
sizes were identified in our study as risk factors for CWL.
Although the differences between complete and incomplete
data sets were significant for tumor site and tumor
localization, the absolute numbers are small. As a result,
the prevalence of CWL in the current study is slightly
underestimated.
With regard to tumor localization, almost one third of the
whole population was categorized as ‘other’ indicating
cancer in the ear or nose or esophagus or salivary glands,
Table 2 Prevalence of critical weight loss per tumor localization
Tumor localization Prevalence of critical weight loss
Percentage Number
Larynx 12 18
Supraglottic larynx 34 13
Glottic larynx 3 3
Sub-/transglottic larynx 22 2
Hypopharynx 43 21
Oropharynx/oral cavity 34 23
Nasopharynx 36 5
Othera 8 10
a Carcinoma in the ear, salivary gland, nose/paranasal cavity, esoph-
agus, thyroid gland, skin, eye, lymphoma and unknown primary.
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etc. As expected, prevalence of CWL in this specific group
was low (8%) because the majority of these tumor local-
izations does not affect the swallowing function and
therefore seldom leads to CWL, except for carcinoma in
the esophagus. Only three patients with carcinoma in the
esophagus were present in the current study, of which two
had CWL. If the group categorized as ‘other’ was excluded
from analysis, the prevalence of CWL in the remaining
group of head and neck cancer patients increased to 24%.
In our opinion, patients with carcinoma in areas not directly
localized in the upper digestive tract do not need to be
screened routinely for CWL at the time of diagnosis.
CWL was present in almost one fifth of the patients.
This prevalence may be lowered if the patient is already
screened for CWL at the general practitioner. In The
Netherlands, CWL during illness is generally poorly
recognized and only half of the malnourished patients are
referred to a dietitian [13]. More attention has to be put into
screening in the general practitioner’s office because a
longer period of nutritional intervention may result in
effective weight gain and a more positive effect on
treatment-related morbidity and mortality.
Patients with a tumor in the hypopharynx, oropharynx/
oral cavity and supraglottic larynx had the highest risk for
CWL, probably related to dysphagia, which was frequently
present in these patient groups in the current study. About
34% of the patients with oral or oropharyngeal cancer
report dysphagia before the start of the treatment [6].
Cancer in the glottic larynx rarely impairs swallowing
function. Therefore, cancer in this localization is seldom
associated with CWL as confirmed by the results of the
current study. Prevalence of CWL was high (36%) in
patients with cancer in the nasopharynx. However, in our
study, only 14 patients had nasopharyngeal cancer. The
high prevalence might be the result of sample variation.
Loss of taste/aversion and loss of appetite were
significantly associated with CWL in the logistic multivar-
iate regression analysis. Loss of taste/aversion and loss of
appetite may be symptoms of the cancer anorexia–cachexia
syndrome [12, 21]. This syndrome is the result of a
multifactorial process involving cytokines, hormones and
neuropeptides [15, 21, 22]. It was suggested that patients
with head and neck cancer may have an elevated cytokine
production related to tumor stage [20, 23]. Future prospec-
tive studies should point out whether CWL at diagnosis is
the result of starvation due to dysphagia and passage
difficulties or the result of the systemic effects of the cancer
anorexia–cachexia syndrome because the effectiveness of
the nutritional intervention may depend on the underlying
mechanisms of the weight loss.
The symptom ‘pain in throat’ was not significantly
related to CWL. This finding may be the result of difficulty
in distinguishing ‘dysphagia’ from ‘pain in throat’ by the
observer or patient. These two symptoms overlap. The
symptoms ‘dry mouth and/or pain in mouth’ were not
significantly related to CWL either, possibly because the
screening was performed at the time of diagnosis, whereas
xerostomia is to be expected during and after treatment with
radiotherapy or chemoradiation [30].




OR 95% CI of
OR
Loss of appetitea 0.87 0.43 2.38 1.03–5.47
Loss of taste and/or aversiona 1.33 0.64 3.80 1.08–13.36
Dysphagia and/or passage
difficultiesa
2.95 0.35 19.12 9.63–37.97
Constant −3.08 0.29 0.05 0.03–0.08
β: regression coefficient, SE β: standard error of β, OR: odds ratio=eβ,
95% CI of OR: 95% confidence interval of odds ratio.
a Absent or present.











%a (n) %a (n) %a (n) %a (n) %a (n)
Larynx (n=139) 6 (8) 4 (6) 16 (22) 17 (23) 7 (10)
Supraglottic larynx (n=34) 12 (4) 9 (3) 47 (16) 47 (16) 12 (4)
Glottic larynx (n=96) 3 (3) 2 (2) 3 (3) 5 (5) 6 (6)
Sub-/transglottic larynx (n=9) 11 (1) 11 (1) 33 (3) 22 (2) 0 (0)
Hypopharynx (n=47) 23 (11) 9 (4) 62 (29) 47 (22) 15 (7)
Oropharynx and oral cavity (n=66) 29 (19) 9 (6) 53 (35) 38 (25) 15 (10)
Nasopharynx (n=12) 8 (1) 0 (0) 42 (5) 17 (2) 17 (2)
Otherb (n=109) 11 (12) 6 (6) 14 (15) 9 (10) 6 (7)
a Percentages are row percentages.
b Carcinoma in the ear, salivary gland, nose/paranasal cavity, esophagus, thyroid gland, skin, eye, lymphoma and unknown primary.
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Prevalence of CWL was highest in patients with a tumor
in the hypopharynx, oropharynx/oral cavity and supra-
glottic larynx, especially in patients with larger tumors.
Nowadays, tumors with tumor size 3 and 4 are mainly
treated with (accelerated) radiotherapy or chemoradiation.
These treatment modalities are accompanied by dysphagia,
odynophagia, xerostomia, taste disorders and loss of ap-
petite. The results of our study have shown that most of
these symptoms are predictive for CWL at the time of
diagnosis. If no nutritional intervention takes place, body
weight will further decline during cancer treatment.
Prophylactic placement of a gastrostomy tube is effective
in reducing weight loss during treatment with radiotherapy
and chemoradiation [11, 16, 24]. When CWL is present at
the time of diagnosis, placement of a gastrostomy tube in
these patients in the period before the start of the treatment
should be considered to optimize nutritional status.
CWL was dichotomized to be able to perform a risk
analysis on clinically relevant weight loss. A gold standard
for the assessment of malnutrition unfortunately does not
exist currently. Weight loss is one of the criteria commonly
used for assessment of the risk for malnutrition. Weight loss
of ≥5% in 1 month or ≥10% in 6 months is a generally
accepted cutoff for clinically relevant weight loss. Weight
loss of ≥5% in 1 month or ≥10% in 6 months is associated
with increased morbidity such as impaired wound healing,
reduced immune function and decreased tolerance to
surgery, radiotherapy and chemotherapy and with increased
mortality [2, 25, 28]. Besides that, weight loss of ≥5% in
1 month or ≥10% in 6 months has a negative impact on
disease-related quality of life and functional status [27].
The cutoff point used was adopted by ASPEN to define
‘nutritionally at risk adults’ [1].
In the current study, the patient was asked for his or her
body weight. Generally, men overestimate body weight
(mean 0.42 kg), whereas women tend to underestimate their
body weight (mean 1.41 kg) [29]. This discrepancy is
related to age. With an increase of age, more body weight is
overestimated by men. Women tend to underestimate their
weight less as age increases [14, 29]. In our study
population, the majority (75%) of patients was male and
the median age in men was 64 years. Men in the age range
of 60 to 69 years overestimate their weight with an average
of 0.31 kg (SD 5.1 kg) [14]. These findings indicate that the
prevalence of CWL in the current study is probably slightly
underestimated.
Although the UMCG H&N CST is valuable, it was not
validated yet. We used involuntary weight loss of ≥5% in
1 month or ≥10% in 6 months as the cutoff point for CWL
because it appeared to be of great prognostic value in the
occurrence of major post-operative complications and is
associated with higher mortality and complication rate [2,
25, 28]. CWL is an indicator of recently developed
malnutrition risk [1, 4]. Chronic malnutrition risk can be
detected by the body mass index (BMI, weight/height2) [26,
31]. Patients with head and neck cancer are at risk for
chronic malnutrition as a result of bad dietary habits due to
excessive drinking and smoking [3]. Therefore, the body
mass index should be added to the screening tool in future
studies.
In conclusion, CWL is already a considerable problem in
head and neck cancer patients at the time of diagnosis.
CWL is in particular frequently observed in patients with
cancer in the hypopharynx, oropharynx/oral cavity and
supraglottic larynx. Symptoms that were strongly related to
CWL were dysphagia/passage difficulties, loss of taste/
aversion and loss of appetite.
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